Overview
- Description
ADmit Therapeutics, S.L. focuses on the development and commercialization of a novel Alzheimer’s disease (AD) early detection technology. It is a spin-off from the Bellvitge Biomedical Research Institute (IDIBELL).
Their IVD test will be provided to pharmaceutical companies, optimizing the patients' recruitment in clinical trials and, consequently, facilitating the identification of effective drugs for AD. ADmit Therapeutics will also work in complementary fields such as Dementia with Lewy bodies and Parkinson Disease, to make its offer more robust and attractive for future acquisitors.
- Website
- Founded
2017
- Project
- Country
- Spain
- Theme
- Health